As seen in Figure 4c, we observed a significant elevation in the IFN-γ and TNF-α production of tumor-specific immune cells in groups administrated with RdB/IL23/p35 compared with RdB/IL12-administrated groups (P<0.01), confirming the results obtained by IFN-γ and TNF-α ELISPOT assay. This evidence concerns the gene TNF and neoplasm.